The safety of trastuzumab deruxtecan (DS‐8201) with a focus on interstitial lung disease and/or pneumonitis: A systematic review and single‐arm meta‐analysis.

MLA

Li, Ruijuan, et al. “The Safety of Trastuzumab Deruxtecan (DS‐8201) with a Focus on Interstitial Lung Disease and/or Pneumonitis: A Systematic Review and Single‐arm Meta‐analysis.” Cancer (0008543X), vol. 130, no. 17, Sept. 2024, pp. 2968–77. EBSCOhost, https://doi.org/10.1002/cncr.35349.

APA

Li, R., Hua, M., Li, J., Chen, W., Xu, L., Meng, H., Zhang, Z., Liu, Q., Cui, Y., & Xiang, Q. (2024). The safety of trastuzumab deruxtecan (DS‐8201) with a focus on interstitial lung disease and/or pneumonitis: A systematic review and single‐arm meta‐analysis. Cancer (0008543X), 130(17), 2968–2977. https://doi.org/10.1002/cncr.35349

Chicago

Li, Ruijuan, Manqi Hua, Jiulong Li, Weihong Chen, Ling Xu, Huan Meng, Zhuo Zhang, Qianxin Liu, Yimin Cui, and Qian Xiang. 2024. “The Safety of Trastuzumab Deruxtecan (DS‐8201) with a Focus on Interstitial Lung Disease and/or Pneumonitis: A Systematic Review and Single‐arm Meta‐analysis.” Cancer (0008543X) 130 (17): 2968–77. doi:10.1002/cncr.35349.